Immuno-oncology technology最新文献

{"title":"Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma","authors":"T.J. Monberg ,&nbsp;S.A. Tvingsholm ,&nbsp;M. Svensson-Frej ,&nbsp;C. Vestergaard ,&nbsp;M. Ormhøj ,&nbsp;J.W. Kjeldsen ,&nbsp;T.H. Borch ,&nbsp;R.B. Holmstroem ,&nbsp;N. Jayashankar ,&nbsp;J.S. Granhøj ,&nbsp;A.R. Cordt ,&nbsp;S.K. Larsen ,&nbsp;Ö. Met ,&nbsp;S.R. Hadrup ,&nbsp;I.M. Svane","doi":"10.1016/j.iotech.2025.101581","DOIUrl":"10.1016/j.iotech.2025.101581","url":null,"abstract":"<div><h3>Background</h3><div>Tumor-infiltrating lymphocyte (TIL) therapy is effective in metastatic melanoma (MM), but the need for resectable tumor tissue limits its accessibility. Antigen-presenting scaffolds (Ag-scaffolds) constitute a technology developed for the specific expansion of tumor-associated antigen (TAA)-specific T cells directly from peripheral blood. Ag-scaffolds are built on a dextran backbone with coattached interleukin 2 (IL-2), interleukin 21 (IL-21), and major histocompatibility complex class I molecules loaded with the top 30 most frequently expressed TAAs in MM patients. The resulting multiple antigen-specific endogenously derived T-cell (MASE-T) infusion product is enriched for CD8+ TAA-specific T cells. We hypothesize that treatment with MASE-T therapy is safe and feasible in patients with immune checkpoint inhibitor (ICI)-resistant MM.</div></div><div><h3>Patients and methods</h3><div>In this phase I, first-in-human, clinical trial (NCT04904185), six patients with ICI-resistant MM received MASE-T therapy preceded by 3 days of lymphodepleting chemotherapy with cyclophosphamide and fludarabine phosphate. The primary endpoint was the safety and feasibility of the treatment.</div></div><div><h3>Results</h3><div>MASE-T cells were successfully expanded in 88% (7/8) of the included patients, and most MASE-T products were enriched for T-cell populations targeting multiple TAAs. Administration of MASE-T therapy was safe with no MASE-T-related toxicities. Clinical efficacy was limited, with 3 out of 6 (50%) patients having stable disease 6 weeks after treatment.</div></div><div><h3>Conclusions</h3><div>This trial demonstrates that Ag-scaffold-driven expansion of TAA-specific T cells from the peripheral blood of patients with MM is feasible, and the resulting MASE-T infusion product can be safely administered. However, further development is required to unleash the full potential of this technology.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101581"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care","authors":"E. Bengala ,&nbsp;D. Santini ,&nbsp;V. Picone","doi":"10.1016/j.iotech.2025.101558","DOIUrl":"10.1016/j.iotech.2025.101558","url":null,"abstract":"<div><h3>Background</h3><div>The combination of botensilimab + balstilimab demonstrated promising clinical activity in heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer (mCRC) in a recently published phase I study (NCT03860272).</div></div><div><h3>Patients and methods</h3><div>Our objective was to derive overall survival (OS), progression-free survival (PFS) and safety data from the trials of reference of the current standard of care for refractory mCRC and from the above-mentioned study, and to compare them. After a systematic search of PubMed, we selected four studies (SUNLIGHT, FRESCO-2, RECOURSE, CORRECT). Individual patient OS and PFS data were extracted from Kaplan–Meier curves and more frequent toxic effect rates were collected.</div></div><div><h3>Results</h3><div>Immunotherapy showed higher efficacy in terms of median OS both compared with trifluridine-tipiracil plus bevacizumab [hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.44-0.89] and to later lines of treatment: fruquintinib, regorafenib, and trifluridine-tipiracil alone. These results were confirmed by median PFS comparison of all the therapies except for the trifluridine-tipiracil + bevacizumab combination (HR 0.46, 95% CI 0.35-0.61 in favor of trifluridine-tipiracil + bevacizumab). As for treatment-related adverse events the most frequent with immunotherapy were fatigue and diarrhea. The other regimens were associated with hematologic toxic effects, nausea, hypertension, and dermatological toxicity.</div></div><div><h3>Conclusion</h3><div>These findings suggest that the immunotherapy combination appears to be a potential option for patients with refractory mCRC while being associated with a completely different toxicity profile. However, confirmation of its efficacy awaits the results of randomized studies. Better comprehension of disease characteristics related to treatment response, such as metastatic sites and molecular biology, is warranted for patient selection.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101558"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis","authors":"S. Haider ,&nbsp;M. Hong ,&nbsp;J. Descallar ,&nbsp;B. Balakrishnar ,&nbsp;T.L. Roberts ,&nbsp;K. Keat ,&nbsp;W. Chua","doi":"10.1016/j.iotech.2025.101559","DOIUrl":"10.1016/j.iotech.2025.101559","url":null,"abstract":"<div><h3>Background</h3><div>Melanoma patients with pre-existing autoimmune diseases (AIDs) have been excluded from clinical trials of immune checkpoint inhibitors (ICIs), due to a risk of flare and immune-related adverse effects (irAEs).</div></div><div><h3>Materials and methods</h3><div>A comprehensive literature search of Medline, Embase, CINAHL and Scopus was carried out. Studies of melanoma patients with pre-existing AIDs were included. Two reviewers used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Outcomes assessed included all-grade and grade 3 or 4 <em>de novo</em> irAEs, AID flare, treatment discontinuation owing to adverse effect(s), treatment-related mortality and objective response rate (ORR).</div></div><div><h3>Results</h3><div>Thirty-two percent of patients with AIDs developed a flare, with 80% requiring immunosuppression. In patients with AIDs, meta-analysis revealed a higher risk of all-grade irAEs [risk ratio (RR) 1.16, 95% confidence interval (CI) 1.01-1.33, <em>P</em> = 0.0106] but not grade 3 or 4 (RR 1.21, 95% CI 0.99-1.47, <em>P</em> = 0.0663). Treatment discontinuation, treatment-related mortality and ORR were not different among patients with AIDs.</div></div><div><h3>Conclusions</h3><div>Melanoma patients with pre-existing AIDs are at significant risk of flare with ICI use. These patients had an increased risk of irAEs of any grade. Although there was a trend towards increased risk of severe irAEs, this was not statistically significant. irAEs did not result in treatment-related deaths, and there were no differences in treatment response. Risks should be discussed, coupled with close monitoring.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101559"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"75eTiP PerceIVe: Power of liquid biopsy tracking in immunotherapy treated unresectable stage III and stage IV melanoma","authors":"A. Javaid ,&nbsp;S. Cheruvu ,&nbsp;P.G. Corrie ,&nbsp;K. Edmonds ,&nbsp;A. Laing ,&nbsp;J. Larkin ,&nbsp;R. Lee ,&nbsp;R. Mair ,&nbsp;A. Modi ,&nbsp;F. Mouliere ,&nbsp;A. Murra ,&nbsp;J. Pozas Perez ,&nbsp;A. Roshan ,&nbsp;D. Rothwell ,&nbsp;M. Wheater ,&nbsp;K. Young","doi":"10.1016/j.iotech.2025.101158","DOIUrl":"10.1016/j.iotech.2025.101158","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101158"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"29P Circulated T cell exhausted subtypes and immunosuppressive tregs predict response in CRC patients","authors":"A. Xagara ,&nbsp;K.P. Efraimidi ,&nbsp;K. Vasilieva ,&nbsp;E. Chantzara ,&nbsp;I. Samaras ,&nbsp;V.N. Papadopoulos ,&nbsp;A. Kotsakis","doi":"10.1016/j.iotech.2025.101112","DOIUrl":"10.1016/j.iotech.2025.101112","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101112"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"102P CD4+ CAR-T cells induceimmunogenic cell death through noncanonical extracellular vesicle","authors":"Y. Wang,&nbsp;H. Xian,&nbsp;H. Liu","doi":"10.1016/j.iotech.2025.101187","DOIUrl":"10.1016/j.iotech.2025.101187","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101187"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"118eP Identification of common cancer antigens useful for cancer specific immunotherapy “cancer vaccine and CAR/TCR-T cell therapy” for primary colorectal cancer and liver metastases","authors":"J. Kataoka ,&nbsp;K. Takenouchi ,&nbsp;T. Suzuki ,&nbsp;K. Ohnuki ,&nbsp;Y. Tsukada ,&nbsp;N. Gotohda ,&nbsp;M. Ito ,&nbsp;T. Nakatsura","doi":"10.1016/j.iotech.2025.101203","DOIUrl":"10.1016/j.iotech.2025.101203","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101203"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2P Diagnostic and prognostic significance of cancer stem cells and inflammatory markers in prostate cancer","authors":"K. Dubey","doi":"10.1016/j.iotech.2025.101087","DOIUrl":"10.1016/j.iotech.2025.101087","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101087"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"96P Expansion of cryopreserved tumor-infiltrating lymphocytes (TIL) from patients with colorectal cancer using serum-free media","authors":"D. Kuznetsova ,&nbsp;T. Petrova ,&nbsp;P. Kovaleva ,&nbsp;D. Ryazantsev ,&nbsp;E. Sharova ,&nbsp;V.N. Lazarev","doi":"10.1016/j.iotech.2025.101181","DOIUrl":"10.1016/j.iotech.2025.101181","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101181"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"14P Immune signature predicts occult invasion in ductal carcinoma in situ diagnosed by vacuum-assisted breast biopsy","authors":"M. Lazzeroni ,&nbsp;F. Conversano ,&nbsp;K. Venetis ,&nbsp;F. Bellerba ,&nbsp;E. Del Fiol Manna ,&nbsp;G. Cursano ,&nbsp;E. Mane ,&nbsp;C. Frascarelli ,&nbsp;M. Risti ,&nbsp;L. Nicosia ,&nbsp;G. Signorelli ,&nbsp;L. Mariano ,&nbsp;C. Zanzottera ,&nbsp;D. Macis ,&nbsp;E. Cassano ,&nbsp;N. Fusco ,&nbsp;B. Bonanni ,&nbsp;P. Veronesi ,&nbsp;S. Gandini ,&nbsp;E. Guerini Rocco","doi":"10.1016/j.iotech.2025.101099","DOIUrl":"10.1016/j.iotech.2025.101099","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101099"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}